Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells.

Zhang X, Gamble MJ, Stadler S, Cherrington BD, Causey CP, Thompson PR, Roberson MS, Kraus WL, Coonrod SA.

PLoS Genet. 2011 Jun;7(6):e1002112. doi: 10.1371/journal.pgen.1002112.

2.

Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.

Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, Davis T, Matesic LE, Thompson PR, Hofseth LJ.

Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G929-38. doi: 10.1152/ajpgi.00435.2010.

3.

N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis.

Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM.

J Immunol. 2011 Apr 1;186(7):4396-404. doi: 10.4049/jimmunol.1001620.

4.

CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation.

Marcos V, Zhou Z, Yildirim AO, Bohla A, Hector A, Vitkov L, Wiedenbauer EM, Krautgartner WD, Stoiber W, Belohradsky BH, Rieber N, Kormann M, Koller B, Roscher A, Roos D, Griese M, Eickelberg O, Döring G, Mall MA, Hartl D.

Nat Med. 2010 Sep;16(9):1018-23. doi: 10.1038/nm.2209. Retraction in: Nat Med. 2011 Jul;17(7):899.

PMID:
20818377
5.

PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps.

Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y.

J Exp Med. 2010 Aug 30;207(9):1853-62. doi: 10.1084/jem.20100239.

6.

Protein arginine deiminase 4: a target for an epigenetic cancer therapy.

Slack JL, Causey CP, Thompson PR.

Cell Mol Life Sci. 2011 Feb;68(4):709-20. doi: 10.1007/s00018-010-0480-x.

7.

Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis.

Kolfenbach JR, Deane KD, Derber LA, O'Donnell CI, Gilliland WR, Edison JD, Rosen A, Darrah E, Norris JM, Holers VM.

Arthritis Rheum. 2010 Sep;62(9):2633-9. doi: 10.1002/art.27570.

8.

Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3.

Knuckley B, Causey CP, Jones JE, Bhatia M, Dreyton CJ, Osborne TC, Takahara H, Thompson PR.

Biochemistry. 2010 Jun 15;49(23):4852-63. doi: 10.1021/bi100363t.

9.

Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation.

Knuckley B, Causey CP, Pellechia PJ, Cook PF, Thompson PR.

Chembiochem. 2010 Jan 25;11(2):161-5. doi: 10.1002/cbic.200900698.

10.

Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.

Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR.

Curr Opin Drug Discov Devel. 2009 Sep;12(5):616-27. Review.

11.
12.

Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation.

Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, Hayama R, Leonelli L, Han H, Grigoryev SA, Allis CD, Coonrod SA.

J Cell Biol. 2009 Jan 26;184(2):205-13. doi: 10.1083/jcb.200806072.

13.

Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4.

Struyf S, Noppen S, Loos T, Mortier A, Gouwy M, Verbeke H, Huskens D, Luangsay S, Parmentier M, Geboes K, Schols D, Van Damme J, Proost P.

J Immunol. 2009 Jan 1;182(1):666-74.

14.

Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.

Proost P, Loos T, Mortier A, Schutyser E, Gouwy M, Noppen S, Dillen C, Ronsse I, Conings R, Struyf S, Opdenakker G, Maudgal PC, Van Damme J.

J Exp Med. 2008 Sep 1;205(9):2085-97. doi: 10.1084/jem.20080305.

15.

Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation.

Loos T, Mortier A, Gouwy M, Ronsse I, Put W, Lenaerts JP, Van Damme J, Proost P.

Blood. 2008 Oct 1;112(7):2648-56. doi: 10.1182/blood-2008-04-149039.

16.

Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis.

Harris ML, Darrah E, Lam GK, Bartlett SJ, Giles JT, Grant AV, Gao P, Scott WW Jr, El-Gabalawy H, Casciola-Rosen L, Barnes KC, Bathon JM, Rosen A.

Arthritis Rheum. 2008 Jul;58(7):1958-67. doi: 10.1002/art.23596.

17.

Regulation of p53 target gene expression by peptidylarginine deiminase 4.

Li P, Yao H, Zhang Z, Li M, Luo Y, Thompson PR, Gilmour DS, Wang Y.

Mol Cell Biol. 2008 Aug;28(15):4745-58. doi: 10.1128/MCB.01747-07.

18.

Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis.

Yao H, Li P, Venters BJ, Zheng S, Thompson PR, Pugh BF, Wang Y.

J Biol Chem. 2008 Jul 18;283(29):20060-8. doi: 10.1074/jbc.M802940200.

19.

Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities.

Wood DD, Ackerley CA, Brand Bv, Zhang L, Raijmakers R, Mastronardi FG, Moscarello MA.

Lab Invest. 2008 Apr;88(4):354-64. doi: 10.1038/labinvest.3700748.

20.

Histone deimination as a response to inflammatory stimuli in neutrophils.

Neeli I, Khan SN, Radic M.

J Immunol. 2008 Feb 1;180(3):1895-902.

Items per page

Supplemental Content

Support Center